CollPlant Biotechnologies (CLGN) EBIT (2017 - 2026)

CollPlant Biotechnologies (CLGN) has reported EBIT for 10 consecutive years, with -$3.1 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 89.02% year-over-year to -$3.1 million; the trailing twelve-month figure through Mar 2026 stood at -$6.6 million (down 14.52% YoY), and the FY2025 full-year result was -$11.5 million, up 33.44% from the prior year.
• EBIT grew to -$3.1 million in Q1 2026 per CLGN's latest filing, from -$3.2 million in the prior quarter.
• Across five years, EBIT topped out at $5.7 million in Q2 2023 and bottomed at -$5.1 million in Q4 2023.
• Historically, EBIT has averaged -$1.1 million across 5 years, with a median of -$3.2 million in 2025.
• The sharpest annual moves came in 2023 and 2025: EBIT soared 235.65% in 2023, then sank 138.07% in 2025.
• Over 5 years, EBIT stood at -$4.7 million in 2022, then decreased by 8.38% to -$5.1 million in 2023, then increased by 21.59% to -$4.0 million in 2024, then rose by 20.73% to -$3.2 million in 2025, then gained by 1.11% to -$3.1 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$3.1 million, -$3.2 million, and -$3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.